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Abstract
Paraplegia is the damage or loss of function in motor and/or sensory abilities. 
This insult can be observed in the thoracic, lumbar, or sacral parts of spinal column. 
Besides, paraplegia may be occurring because of any injuries or diseases of the 
lower segments or peripheral nerves or by cerebral palsy (CP). This damage can 
be seen as a result of a tumor or blood clot on the spinal cord. By now, there is not 
any curative treatment for paraplegia. Using mesenchymal stem cells (MSCs) in 
the treatment of spinal cord injury is a promising tested strategy because of their 
simplicity of isolation/preservation and their properties. Several preclinical studies 
in this field can be found; however, MSCs showed weak and conflicting outcomes in 
trials. In this chapter book, we will discuss about the therapeutic role of these cells 
in the treatment of paraplegia, with emphasis on their characterization, relevance, 
boundaries, and prospect views.
Keywords: paraplegia, stem cell therapy, mesenchymal stem cell, preclinical study, 
clinical study
1. Introduction
Paralysis of the lower parts of the body (paraplegia) can be caused by any damage 
to the spinal cord [1, 2]. Traumatic and nontraumatic injuries are classifications of 
this disease [3]. Paraplegia causes severe and in most cases lasting changes in the 
patient’s lifetime and lifestyle [4, 5].
Attempts to find a complete cure for paraplegia and several discoveries show 
that in adult mammalian, by the preparation of appropriate microenvironment, 
regeneration of spinal cord axons can be obtained [6]. But then, why can we see 
the huge delay in the processing of bench to bedside in spite of these findings? 
Unfortunately, spinal cord scientists find a new barrier in the regeneration field. In 
fact, axons do regenerate up and down through a graft or transplant placed at the 
damage site; however, when they reach healthy cord tissue beyond the injury zone, 
they fail to regenerate more at once [7]. The most important cause for this provi-
sion is that the axons of neural networks need to cross through during sufficient 
stabilized conditions which are unreceptive and intractable to new restoration. 




Recently, rapid progresses in multipotent stem cell (routinely called mesenchymal 
stromal/stem cells) investigations increase the interest of scientists to study about the 
cell therapy and regenerative medicine [9–11].
Mesenchymal stem cell transplantation in patients suffering paraplegia is con-
sidered as a strategy for increasing neuroregeneration [12–14]. Notably, because of 
the disproportion in the technique and method of MSC preparation for paraplegia 
treatment like how they administrate and which criteria are chosen for selecting 
patients, MSC transplantation is in the initial stages, and there is confusion about 
the consequences at present [15].
MSCs have various sources in the body including the bone marrow [16, 17], 
adipose [18], muscle [19], peripheral blood [20], umbilical cord [21–23], placenta 
[24], endometrial [25, 26] and menstrual blood [27–29], fetal tissue [30], and 
amniotic fluid [31]. Previous finding indicated that these clonal cells can adhere 
to plastic; express cluster of differentiation (CD) markers like CD73, CD90, and 
CD105 markers [32]; and can differentiate into adipogenic [33], chondrogenic [34], 
osteogenic [35, 36], and neurogenic [37–39] lineages in the experimental condition 
(in vitro). However, it can be observed many different reports in their strength 
and self-renewal potential [40]. Accordingly, when we compare previous surveys, 
variable or even conflicting results can be seen. The lack of uniform methods in MSC 
characterization, both in preclinical and clinical studies, contributes to this confu-
sion. It is interesting that even the name “MSCs” has still been gradually questioned. 
Actually, an urgent demand is required to understand the novel sources and poten-
cies of MSCs especially for applying in SCI treatment.
Previous findings showed that the optimistic effect of MSC in treatment of 
spinal cord and peripheral nerve injury ascribed to their differentiation ability. 
They can differentiate into various cell lineages and modulate the inflammation 
process and immunomodulatory responses. [41] MSCs can diminish cell apoptosis 
and secrete various neurotrophic factors [42, 43].
According to previous studies, transplanting enough cells is important to obtain 
the best outcome after MSC transplantation and also applying especial techniques 
for achieving the highest possible survival of MSCs. Likewise, it seems that repeated 
doses of MSC therapy might be helpful [44].
Findings obtained about clinical trials for SCI treatment demonstrated that 
the efficacy of MSCs in human studies is not beneficial like in preclinical studies 
[45]. For these reasons protocol standardization of basic and preclinical studies 
using MSCs should emphasize to translate to the clinical setting. This chapter book 
is based on preclinical studies and clinical trials dealing with MSC therapy for 
paraplegia with emphasis on the challenges in this field.
2. Paraplegia: mechanisms of degeneration
SCI is included in two mechanisms: primary and secondary damage. When the 
direct physical injury to the spinal cord happened like any contusion, compression, 
contraction, and laceration, it can be called primary injury [46]. In this condition, 
axons separate from each other, mechanical injury to cells occurs directly, and blood 
vessels rupture. The progress of the injury site can occur in secondary phase, and 
it can be led to the restorative process [47]. This phase is including alterations in 
concentration of local ionic, blood pressure dysregulation (local and systemic), 
decrease of blood flow in the spine, disruption in the blood-brain barrier (BBB), 
diffusion of proteins from serum into the spinal cord, alterations in inflammatory 
chemokines and cytokines, cell apoptosis, excitotoxicity, activation of calpain 
proteases, accumulation of neurotransmitter, production of free radicals, lipid 
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peroxidation, and activation of matrix metalloproteinases (MMPs). All of these 
changes can lead to demyelination of axons and also ischemia, necrosis, and 
apoptosis of spinal cord tissue [48]. As a result of these alterations, the inhibitory 
prospect overcomes, and axonal regrowth constrains. By this reason, injured axons 
cannot regenerate for a second time [49].
3. Mesenchymal stem cells: a historical outline
The pathologist Cohnheim in 1867 could show the first evidence of nonhematopoietic 
stem cells in the bone marrow (BM) and their potency to be the source of fibroblasts 
involved in wound healing [50]. However, only a century later (50 years ago), the isola-
tion and culture of these cells in an experimental condition successfully could be done. 
Friedenstein and his colleagues found that, when isolated cells from the rat bone marrow 
are cultured, a population of fibroblastic-shape nonhematopoietic cells that adhered to 
the plastic of the cell culture dish could be seen. Then these cells were called as a colony-
forming unit fibroblast (CFU-F). These cells were capable of self-maintenance and 
multi-lineage differentiation like adipocytes, chondrocytes, and osteocytes in vitro and 
also could support hematopoietic stroma when a single cell was transplanted into animal 
models [51]. In 1988, Owen showed that a stromal system existed, with a stromal stem 
cell (CFU-F) at the base of the hierarchy, popularizing the stromal cell terminology [52]. 
Altogether, this information was generated from in vivo studies.
Only in 1992, Haynesworth and his colleagues enriched and expanded cells in 
culture with the osteochondrogenic potential of the human bone marrow [53]. In 
the early 1990s, the proliferation and differentiation potency of these cells in an 
experimental condition and also multipotency and self-renewal properties after 
transplantation lead to characteristics of the “stemness” [54]. Thus, the term mes-
enchymal stem cell (MSC) was proposed by Caplan for progenitor cells, which were 
isolated from the human adult bone marrow (BM) instead of the term “stromal” or 
“osteogenic” stem cell and acquired a broad recognition [55]. Figure 1 shows the 
representation of the most imperative results related to MSC discovery, character-
ization, and clinical relevance.
Figure 1. 




4.  Preclinical researches using mesenchymal stem cells for paraplegia 
treatment
Transplantation of MSCs has been well established by several researchers. MSCs 
have significant effects on the several cellular and molecular cascades. Therefore, 
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they can be regarded as a possible candidate for treating of CNS diseases [56]. MSCs 
have anti-inflammatory representation [57], immunomodulatory regulation [58, 59], 
and neuroprotective [60] effects. Moreover, previous findings showed that these cells 
could secrete trophic factors; thus they could motivate axon regeneration finally lead-
ing to functional recovery improvement [61, 62].
Regarding to the paracrine effect, MSCs can produce trophic and neurotropic 
factors such as insulin-like growth factor (IGF), brain-derived neurotrophic factor 
(BDNF) [63], vascular endothelial growth factor (VEGF) [64], granulocyte-
macrophage colony-stimulating factor (GMCSF), fibroblast growth factor-2 (FGF2) 
[65], and transforming growth factor beta (TGF-β) [66]. In addition, gene therapy 
is another field that MSC therapy can be combined with, for example, introducing 
special genes into MSCs to generate molecules that have great curative ability and 
can increase neural survival and regeneration [67, 68]. Table 1 presents a summary 
of preclinical studies by applying MSCs for paraplegia.
5. Clinical trials using mesenchymal stem cell for paraplegia
The clinical trials conducted for the treatment of paraplegia include three different 
phases. Phase 1 trials begin with the cell transplantation to a human participant, and 
the aim of these trials is to study any events such as adverse or toxic effects and also 
the safety of this intervention. During these trials, subjects may be exposed to some 
risks and obtain low benefits at the end. In phase 2, the goal of the trial is to determine 
the potential and variety of an intervention compared to a control group. Typically, 
the participants are recruited and arbitrarily assigned to the groups as experimental 
or control, and both participants and investigators are in blind condition, which 
means they do not have any insight about which of them have been assigned [86]. In 
phase 3, the conclusive clinical trial and the objective normally affirm the preliminary 
results obtained at the phase 2, with a significant clinical profit of the therapeutic 
intervention which has been proved by statistic methods. The number of participants 
is also larger, and manifold centers are elaborated in the trial [87]. By now, the majority 
of the studies using MSCs for paraplegia treatment are in phase 1 or 2 (Table 2).
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Title Lesion type Cell source Phase of the 
study
Effects on neural regeneration ClinicalTrials.
gov identifier
Safety study of local administration of 
autologous bone marrow stromal cells in 
chronic paraplegia (CME-LEM1)





Motor enhancement, alteration in the chronic 
pain, improvement of neurophysiological 
parameters, and morphology changes in the 
spinal cord on neuroimaging follow-up
NCT01909154
Autologous mesenchymal stem cells 
transplantation in thoracolumbar chronic and 
complete spinal cord injury spinal cord injury
Thoracolumbar 






Phase II, not 
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Not informed NCT02574585
Autologous mesenchymal stem cells 
transplantation for spinal cord injury—a phase 
I clinical study
Traumatic spinal 




Completed Intrathecal administration of BMMSCs is safe 
with no adverse events
NCT02482194
The effect of intrathecal transplantation of 
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Mild improvements in neurological function, 
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NCT01624779
Phase I, single center, trial to assess safety 
and tolerability of the intrathecal infusion of 
ex-vivo expanded bone-marrow derived MSCs 
for the treatment of SCI







Study the safety and efficacy of bone marrow 
derived autologous cells for the treatment of 
SCI
SCI clinical diagnosis Autologous bone 
marrow MSCs
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Phase I study of autologous bone marrow stem 
cell transplantation in patients with spinal cord 
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Phase I Transplantation of autologous BMSCs is a 
feasible and safe technique
NCT01325103
Surgical transplantation of autologous bone 
marrow stem cells with glial scar resection 
for patients of chronic SCI and intra-thecal 











Title Lesion type Cell source Phase of the 
study
Effects on neural regeneration ClinicalTrials.
gov identifier
Autologous adipose derived MSCs 
transplantation in patient with spinal cord 
injury






Intravenous administration of AD-MSCs is safe 
with no adverse events
NCT01274975
Difference between rehabilitation therapy 
and stem cells transplantation in patients with 
spinal cord injury in China
Traumatic injury, 
spinal cord injury
U-MSCs Phase II, 
completed
Patients receiving U-MSCs demonstrate 
improved urinary control, muscle tension, 
motion, and self-care ability
NCT01393977
Table 2. 
Summary of trials using mesenchymal stem cell for treatment of paraplegia.
9
Mesenchymal Stem Cell Therapies for Paraplegia: Preclinical and Clinical Studies
DOI: http://dx.doi.org/10.5772/intechopen.93249
Currently, clinical trials with applying mesenchymal stem cells for treatment of 
paraplegia are growing, suggesting that despite the existence of numerous questions 
at primary and preclinical levels, the MSC is considered supposedly valuable for 
translational researches [46].
6.  Why mesenchymal stem cell functions do not soundly shift these cells 
toward clinic yet?
It is well established that, despite promising preclinical findings about mesen-
chymal stem cells, clinical trials failed to be impressive in SCI treatment and are still 
away from obtaining behavioral and functional improvement and repairing neural 
circuits totally [88].
Regarding the previous researches, studies using animal models are usually 
performed by applying standardized protocols of lesions, treatments, and specific 
timings of transplantation in each group of investigation [89]. However, these con-
ditions are often incomparable with human subjects because timing and therapies 
are dependent on emergency setting and many variables such as lesion site damage 
at the cord [90]. Most of animal studies are necessarily done with rodents such as 
mice and rat, and, despite many anatomical or behavioral similarities, clinical trials 
with human participants should be the main goal of stem cell research. Therefore, 
making a strong bridge between preclinical and clinical studies is mandatory for 
finding the best trail in cell therapy [91].
As well, it is necessary to run more rigorous clinical trials such as RCTs and also 
animal researches in providing MSC therapy as a safe, effective, and beneficial 
approach for various diseases. Already, completed human trials displayed only 
limited outcome. However, applying MSCs in SCIs seems to cause no harm. Different 
trials [92, 93] indicated the safety of MSC therapy showing no side effects [94]. 
Regardless of these findings about safety of stem cell therapy, clinical outcomes 
showed poor results compared to expectations. Among the others, it seems that not 
many studies particularly encourage cell therapy [95].
Consequently, ongoing trials will almost certainly help and develop compre-
hension about the outcomes of stem cell therapy [96]. Unfortunately, translation 
of encouraging data from preclinical studies into clinical administration seems 
intricate. This probably reflects the multivariable and sophisticated paraplegia 
physiopathology, requiring a multi-aspect curative approach. To tell the truth, 
many points require further illuminating and depicting, such as:
1. The best therapeutic protocols with respect to the preparation method, type, 
and amount of stem cells transplanted.
2. The paracrine effects and their impact on behavioral and functional  
improvement.
3. The rout of stem cell delivery and timing of transplantation.
4. The substance of cellular matrix and microenvironment.
5. The ability of neuroplasticity and production of new connections from injured 
neuronal cells.




As a result, prospect preclinical and clinical studies based on MSCs should put 
emphasis on multivariable factors [98]. For instance, considering donor-related 
properties like sex, age, and comorbidities that may have an effect on the capacity and 
excellence of cells is important. Moreover, a better appreciation of the accurate and 
beneficial methods of action calling for ad hoc investigations will also able to scruti-
nize MSC complexity, for instance, stem versus stromal. MSC interactions with host 
tissues have to be considered too. The development of precious in vitro and in vivo 
models is to be applied in a number of medical conditions; and choosing reagents and 
techniques that may be administrated from experimental studies to clinical devel-
opments for preserving cell consistency and eventually reducing manufacturing 
expenses is imperative markedly [99].
7. Conclusion
Nowadays, the advancements in cell marketing with the progress in cell 
isolation, description, and quality control will positively encourage scientists to 
apply MSCs for treating several diseases and disorders, even with all remaining 
challenges.
Preclinical studies revealed the importance of MSC therapy in the SCI and 
paraplegia field. Unluckily, the effect of MSC therapy is not typically seen in the 
human studies, and the results need a long time from being similar to preclinical 
studies. Consequently, among other concerns, the protocol standardization in 
source of cells, culture conditions, time of cell delivery after paraplegia, number 
and administration rout of cells, plasticity, and potential of MSCs after isolation and 
expansion in vitro is of urgency. Confidently, preliminary studies with emphasis on 
these key points will be helpful in terms of their winning implementation of human 
studies.
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